clinical trial · NCT07456033
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
GlaxoSmithKline·phase3·not yet recruiting·n = 456
AsthmaDepemokimabPlacebo
brief summary
The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
started
Mar 6, 2026
primary completion
Jul 1, 2030
completion
Jul 1, 2030
last updated
Mar 6, 2026
official title
The MODIFY Study: A Phase 3b/4 Randomized, Double-blind, Placebo-controlled, Multi-centre Study Evaluating the Impact of Early Intervention With Depemokimab on Exacerbation Rate, Clinical Remission, Lung Function Decline, and Safety in Adults and Adolescents With at Risk Type 2 Asthma, Conducted up to 156 Weeks
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol